Panitumumab-IRDye800 in Detecting Cancer in Participants With Lung Cancer During Surgery

Part of paid clinical trials in Palo Alto, California.

Sponsor
Stanford University
Study ID
NCT03582124
Phase
PHASE1/PHASE2
Status
Recruiting
Apply to this trial

Conditions

  • Lung Carcinoma
  • Metastatic Malignant Neoplasm in the Lung
  • Stage IV Lung Cancer AJCC v8
  • Stage IVA Lung Cancer AJCC v8
  • Stage IVB Lung Cancer AJCC v8

Eligibility Criteria

Sex
ALL
Age
19 Years - N/A
Healthy Volunteers
Not accepted

Interventions

  • Near-Infrared Fluorescence Imaging — PROCEDURE
    Undergo imaging
  • Panitumumab-IRDye800 — DRUG
    Given IV
  • Pharmacokinetic Study — OTHER
    Correlative studies
  • Therapeutic Conventional Surgery — PROCEDURE
    Undergo surgery

Study Details

This phase I/II trial studies the best dose and timing of panitumumab-IRDye800 in detecting cancer in participants with lung cancer during the surgery. Panitumumab-IRDye800 is a combination of the antibody drug panitumumab and IRDye800CW, an investigational dye that can be seen using a special camera. Panitumumab-IRDye800 may attach to tumor cells and make them more visible during surgery in patients with lung cancer.

Key Dates

Start date
Jul 19, 2018
Status verified
Feb 2026
Primary completion
Sep 30, 2026
Completion
Sep 30, 2026

Study Design

Enrollment
30 participants (estimated)
Allocation
NA
Intervention model
SINGLE_GROUP
Primary purpose
DIAGNOSTIC

Arms

  • Experimental: Diagnostic (panitumumab-IRDye800, surgery, NIR)
    Participants receive panitumumab- IRDye800 IV over 60 minutes on day 0, and then undergo NIR and surgery within 1-5 days.

Primary Outcome Measure

Tumor to background ratio (TBR), measured in ex vivo tissues [ Time Frame: Up to 1 year ]

Central Contacts

Locations (1)

FacilityCityStateZIPSite coordinators
Stanford University, School of MedicinePalo AltoCalifornia94304
Natalie Lui
[email protected]
650-721-2086
Natalie Lui (PRINCIPAL_INVESTIGATOR)

Find similar trials in Palo Alto, CA

By condition
Lung cancer
By specialty
OncologyLung oncologyLung disease
By research site
Stanford University, School of Medicine· Palo Alto, CA

Related Studies